c-Mpl Rabbit anti-Human, Mouse, Rat, Polyclonal, Invitrogen
Rabbit Polyclonal Antibody
Manufacturer: Invitrogen PA551118
c-Mpl / CD110 Polyclonal Antibody detects endogenous levels of c-Mpl / CD110 protein.In 1990 an oncogene, v-mpl, was identified from the murine myeloproliferative leukemia virus that was capable of immortalizing bone marrow hematopoietic cells from different lineages. In 1992 the human homologue, named, c-mpl, was cloned. Sequence data revealed that c-mpl encoded a protein that was homologous with members of the hematopoietic receptor superfamily. Presence of anti-sense oligodeoxynucleotides of c-mpl inhibited megakaryocyte colony formation. The ligand for c-mpl, thrombopoietin, was cloned in 1994. Thrombopoietin was shown to be the major regulator of megakaryocytopoiesis and platelet formation. The protein encoded by the c-mpl gene, CD110, is a 635 amino acid transmembrane domain, with two extracellular cytokine receptor domains and two intracellular cytokine receptor box motifs. TPO-R deficient mice were severely thrombocytopenic, emphasizing the important role of CD110 and thrombopoietin in megakaryocyte and platelet formation. Upon binding of thrombopoietin CD110 is dimerized and the JAK family of non-receptor tyrosine kinases, as well as the STAT family, the MAPK family, the adaptor protein Shc and the receptors themselves become tyrosine phosphorylated.
|Synthesized peptide derived from the Internal region of human CD110.|
|Antigen affinity chromatography|
|Human, Mouse, Rat|
|ELISA, Western Blot|
|PBS with 0.5% BSA, 50% glycerol and 0.02% sodium azide; pH 7.4|
|MPL, TPOR, Thrombopoietin receptor, TPO-R, Myeloproliferative leukemia protein, Proto-oncogene c-Mpl, CD110|
|-20° C, Avoid Freeze/Thaw Cycles|
|17480, 366455, 4352|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok